Why Creating A Cure Is Difficult
Experts suggest that even if antiviral drugs destroy the active parts of the infection, it only takes a small amount of the virus to hide in the nerve cells and become dormant for the herpes virus to continue.
To find a treatment, scientists need to understand further the mechanism that enables the infection to hide. By preventing this mechanism, they might be able to tackle the whole infection before parts go dormant.
Some medications may reduce the frequency and severity of symptoms and lower the chances of passing the infection on to others. Current antiviral medications to treat herpes include the following medications:
first form of treatment for HSV infections. A doctor may treat a skin or mucous membrane infection with oral acyclovir, provided the person has a competent immune system.
People with high levels of stress or trauma may experience more frequent recurrences of genital herpes. In this case, a doctor may advise psychotherapy and counseling.
Some home remedies, such as petroleum gel or essential oils, may alleviate the discomfort that herpes lesions cause.
Natural Novel Approach To Herpes May End The Worlds Prevalent Virus
It has taken hundreds of years and billions of people being infected for there to finally be a ray of light in the herpes simplex virus field. A recent study at the Virology, Emerging Diseases & vaccines conference in Canada benchmarked a discovery in the battle to overcome herpes. All be it a natural protocol, it brings with it new hope that could be the long awaited game changer. The protocol produced by Synergy Pharmaceuticals has been able to show promising results across the general population.
Critically important is how well it compares to the standard antiviral medications, involving one of three types of FDA-approved medications acyclovir, valacyclovir, or famciclovir. For those suffering from herpes the medications are used in one of two therapeutic approaches. In episodic therapy, the patient starts taking their prescribed medication at the first sign of an outbreak. Theyll only continue medicating until the outbreak subsides, which is usually just a few days. In suppressive therapy, patients take antiviral medications every day, which has been shown to reduce the severity of outbreaks by 70%.
The HSV story of vaccines so far
The alternative medicine great debate
This article was written in cooperation with Synergy Pharmaceuticals
Genital Herpes Treatment Market
The global genital herpes treatment market is expected to grow at a CAGR of 3.76% during 2022-2028. The Acyclovir segment reported a significant share of around 50% among all drug types. The retail pharmacy segment is showing the highest share due to the availability of branded and generic versions of all antiviral drugs.
Could The Cure For Herpes Be Just What The Doctor Ordered For Synergy Pharmaceuticals
Nearly 800,000 people are newly infected with herpes each year and, in 2011, Roger was one of those people. He was intentionally infected with HSV-2 and suffered several painful outbreaks each year. He was convinced his life was permanently altered and he fell into a depressive state. But, determined to overcome the virus, he formulated a combination of natural ingredients that gradually reduced his outbreaks and then completely removed the virus from his bloodstream. He passed his findings on to officials at Australian biopharmaceutical company Synergy Pharmaceuticals, who conducted clinical trials from 2014 2017 inclusive. The outcome from the trials proved to be the breakthrough in delivering the long awaited negative IgG results for sufferers. Finally, after years and years of stumbles, false starts, and ethical crises, the medical industry had a cure for herpes. So, why havent more professionals supported it?
Synergy Pharmaceuticals and the cure
The results were verified in a series of clinical tests involving randomly selected herpes patients from 2014 2017. The patients were tested for the IgG herpes antibody after taking a single natural ingredient and after taking five natural ingredients. There was no noticeable improvement in taking the single-ingredients, but 70% of patients were herpes-free after a few months of the combined five-ingredient treatment.
The failure of Rational Vaccines
Overcoming biases against alternative medicine
Clinical Trials: Key To Genital Herpes Research
Although these new genital herpes treatments are just on the horizon, it may be years before any are available to consumers.
The process of introducing a new treatment to the public can be a long one. Before the FDA approves a drug, it must go through rigorous clinical trials, which are divided into three phases. In phase I, researchers try to find out if the drug is safe for people to take. If the drug is deemed safe, it may go on to phase II, when researchers aim to determine if the drug works as it should. They also collect more safety data. In phase III trials, they expand their research to include more patients in more places.
To conduct a clinical trial, scientists need people to participate voluntarily. Clinical trials often involve thousands of patients who volunteer to take the experimental drug. The FDA and an independent review board carefully monitor every aspect of the trial. There are rules the researchers must follow to ensure that their work is scientifically correct and ethically sound. Study volunteers have clearly defined rights, such as the right to drop out of the trial at any time.
Recommended Reading: What To Use For Herpes Outbreak
Synergy Pharmaceuticals Herpes Treatment Renews Hope For A Cure And Ignites Debate In Pharmaceutical Industry
For those who contract herpes simplex in any of its forms, the virus is generally considered a lifetime sentence defined by unpredictable flareups and endless rounds of medication. However, a major treatment breakthrough from Australian research and product development company Synergy Pharmaceuticals suggests that herpes may be curable. News of this medical breakthrough could lead to a windfall for Synergy, but in addition to its impending success, the company is also tasked with overcoming criticism from many within the medical community.
A young company restores hope
Whereas previous drug trials focused on finding a vaccine for the herpes virus, Synergy Pharmaceuticals focused on finding a holistic solution for existing herpes patients, and the approach generated unprecedented results.
The company used a five-part treatment, the Combination Herpes Treatment, crafted from L-Lysine, Tribulus, Astragalus, Rhodiola, and a Unique Amino Formula. The special combination of natural ingredients generated T cells which helped break down herpes viral envelope and weakened the virus to the point of erasure. Essentially, the combination treatment prevented cell-to-cell infection and suppressed the virus overall activity.
Synergy Pharmaceuticals research showed a significant result in 72% of test cases. Patients involved in the study had been infected for several years and ingested the five core compounds as directed for six months.
The race for a cure
A Cure For Herpes There Is Progress To Report
It takes a persistent scientist to stop a persistent virus.
A decade ago, Fred Hutchinson Cancer Research Center virologist Dr. Keith Jerome began exploring the idea that lifelong infections with herpes viruses might be cured by using the DNA-cutting tools of gene therapy.
Initial research showed these techniques could knock out small quantities of latent virus, and the work of improving the results fell to Jeromeâs senior staff scientist, Dr. Martine Aubert. Five years ago, the team reported they had damaged the genes of 2%-4% of herpes virus in infected mice. Aubertâs work was an important proof of principle, but far short of a cure.
Nevertheless, she persisted.
On Aug. 18, the team led by Jerome and Aubert published a paper in Nature Communications showing that, through a series of incremental improvements on their original method, they had destroyed up to 95% of herpes virus lurking in certain nerve clusters of mice.
âThis is the first time that anybody has been able to go in and actually eliminate most of herpes in a body,â said Jerome, who is also spearheading research at Fred Hutch and the University of Washington on COVID-19. âIt is a completely different approach to herpes therapy than anybodyâs ever had before.â
Primary And Secondary Immune Responses To Hsv
Innate Immune Response
The innate immune system consists of a variety of components including neutrophils, natural killer cells, monocytes, dendritic cells, macrophages, and the complement cascade . It is the first line of defense against pathogens. A strong innate immune response to foreign antigens is essential to the development of the adaptive humoral and cellular responses of long-lasting immunity . Adjuvants are added to subunit vaccines to elicit an innate response for this purpose. Pattern recognition receptors on host cells allow for the detection and response to viral infections. On binding to pattern recognition receptors , signal transduction leads to the production of various proteins including interferons . Interferons are glycoprotein signaling molecules produced by infected cell lines. They act locally, priming viral defense mechanisms within local cells .
HSV-1 is known to have multiple ligands that bind TLRs, leading to activation of the NF-kB pathway . However, herpes simplex virus is also known to evade the innate immune responses, specifically TLR signaling and interferon production to further viral proliferation . Additionally, a critical aspect of the innate immune system that contributes to the adaptive response is antigen presentation. HSV infection can stimulate autophagy, leading to a more efficient presentation of antigens. However, HSV-1 ICP34.5 gene product antagonizes the response by binding Beclin 1 , essential to autophagy .
Replication Defective Virus Vaccine
Dl5-29 is a strain of HSV-2 with mutations in essential viral genes UL5 and UL29 making it replication defective. It was tested as both a prophylactic and therapeutic vaccine. It was shown to be safe, producing neutralizing antibodies and CD4+ T-cell responses in seronegative subjects who were vaccinated . Recent studies have demonstrated the production of antibodies mediating NK cell activation. Additionally, HSV-2 gD antibodies were detected in cervicovaginal fluid at around one-third of the serum level .
Also Check: How Can I Get Tested For Herpes
Top Review Highlights By Sentiment
- Good benefits and working culture”
- There are no cons to display at this time.
Positive culture and smart RBDs.
We ran out of money.
interesting work and good team
no major cons had good experience
The family atmosphere and the reliance on one another to achieve goals that even large companies with hundreds of employees stuggle with.
Heavily regulated by investor influence. Small companies are often reliant on their stream of income to reach the next level in business and Synergy is ne exception to the rule.
Good benefits, great team atmosphere, highly qualified colleagues and mostly good management. The drug is a good product, too, but has to be commercialized better for the company to stabilize in 2018/19.
Lack of communication from corporate to general employees makes for an uncertain work environment, despite immediate supervisors trying to assuage employee fears of restructuring or down-sizing.
Crew down in Wayne is fun to work with but NY has a weird vibe. Salary and benefits decent- best HR lady left. Looks like they have a good drug.
Spend a lot of money on marketing side. CMO not to be trusted. CEO nice and engaging- but not sure he is in the lead. Fired the whole clinical group from the CIC program right when the drug got approved. What’s that about??
Hsv Pathogenesis And Replication
Replication is a multi-step process. Post-infection, HSV glycoproteins interact with and attach to the cell. The viral envelope then fuses with the cell membrane, releasing its contents into the cell. DNA is uncoated and transported into the nucleus when nucleocapsid fuses with the viral envelope . Here, immediate-early genes are transcribed . Primary herpes infection involves replication within epithelial cells, with an incubation period of 46 days. Mature virions are then transported to the cell membrane, where they are released, causing cell lysis and local inflammation. Replication continues until host immune responses contain the initial infection .
Herpesvirus ascends peripheral sensory nerves to spread to the trigeminal ganglion, where latent infection develops. Latent virus can be induced to reactivate. Reactivation has been associated with various stimuli including stress, infections, and UV light exposure. However, from a molecular standpoint, reactivation is a phenomenon that continues to be studied and is not clearly understood. Clinical manifestations of reactivation vary widely in terms of presentation and severity .
Don’t Miss: How To Control Genital Herpes
Herpes Vaccines And Hiv
People with HSV-2 infection are at least three times more likely to become infected with HIV if exposed. Thus, interventions targeting HSV-2, such as new HSV vaccines, have the potential for additional benefit against HIV, which could be particularly powerful in regions with a high incidence of co-infection.
Content sources: The WHO, US CDC, WHO, NIH, research papers, ClinicalTrials.gov, and the Precision Vaccinations news network. Content is fact-checked by healthcare providers, such as Dr. Robert Carlson.
A Workhorse Of Gene Therapy
The researchers also refined their methods of transporting the molecular scissors to targeted nerve cells. From the beginning, Jerome and his team have relied on a harmless, hollowed-out virus that is drawn to the surface proteins of nerve cells. Called an adeno-associated virus vector, or AAV, it is the little workhorse of gene therapy. In this case, it is used to ferry to the infected nerve cells genetic instructions that cause them to make those meganucleases.
âWe inject the AAV vector, and it finds its way,â Aubert said.
Latent herpes viruses lurk in clusters of nerve cells called ganglia, and researchers have found that some ganglia are harder to reach than others. Over the years, they discovered that some AAV strains are better suited than others to find specific types of nerve clusters, and this has helped them fine-tune the selection of these delivery viruses to match infected cells in different places.
In their mouse experiments, the team continued to improve their results, nudging them up to a 95% reduction in herpesvirus infection in one prominent nerve cluster using a selection of two different meganucleases carried by three different flavors of AAVs. By selecting vectors that are primed for harder-to-reach nerve clusters, the group expects to continue improving their ability to eradicate the virus.
Stoddard is also tweaking the meganucleasesâ structures to make them a better fit against HSV-2.
Aubert said that comes naturally to her.
Recommended Reading: How To Soothe Genital Herpes Pain
Synergy Pharmaceuticals Introduces The Small Step For Natural Medicine One Giant Leap For Ending Herpes
Melbourne, Australia, Aug. 16, 2021 — Synergy Pharmaceuticals is proud to introduce its product against herpes, as nearly 800,000 people are newly infected with herpes each year. During 2011, Roger was one of those patients. He was intentionally infected with HSV-2 and suffered several painful outbreaks each year. He was convinced his life was permanently altered and he fell into a depressive state. But, determined to overcome the virus, he formulated a combination of natural ingredients that gradually reduced his outbreaks and then completely removed the virus from his bloodstream.
He passed his findings on to officials at New York City-based biopharmaceutical company Synergy Pharmaceuticals, who conducted clinical trials and confirmed that the right holistic treatment could indeed cure herpes. Finally, after years and years of stumbles, false starts, and ethical crises, the medical industry had a cure for herpes. So, why havent more professionals supported it?
Synergy Pharmaceuticals Introduces the Product Against the Herpes Virus
Rogers results were verified in a series of clinical tests involving randomly selected herpes patients. The patients were tested for the IgG herpes antibody after taking a single natural ingredient and after taking five natural ingredients. There was no noticeable improvement after taking the single-ingredient treatment, but 80% of patients were herpes-free after a few months of the five-ingredient treatment.
The Controversy of Vaccines
Herpesviruses Association With Pre
On May 11, 2022, a study published in Diabetologia examined the prospective association of herpesviruses with diabetes to evaluate their potential role in diabetes etiology. Conclusions/interpretation: The associations of HSV2 and cytomegalovirus serostatus with diabetes incidence indicate that these herpesviruses may contribute to the development of impaired glucose metabolism. These study results highlight the link between viral infection and diabetes.
Also Check: What Cream Is Used For Genital Herpes
Herpes Vaccines For 2022
Developing protective herpes simplex virus vaccines has been an ongoing challenge for decades. Various herpes vaccine candidates are based on DNA, modified mRNA, protein subunit, killed virus, and attenuated live virus vaccine technologies.
However, there are various clinical trials actively recruiting participants.
Approaches To Vaccine Development
Although there are no currently available vaccines for herpes simplex 1 and 2, there are various candidates in both the pre-clinical and the clinical phases currently in development. Vaccines are being developed with two broad focuses: preventative and therapeutic, some with a dual use. Preventative vaccines are focused on the prevention of primary infection in a seronegative subject. Therapeutic vaccines aim to prevent HSV reactivation, decrease the number of recurrences, or to reduce the severity or duration of clinical symptoms . With regard to vaccine development, given our knowledge of the immunology surrounding HSV, it seems that an effective vaccine would likely stimulate not only humoral responses, but also cell-mediated responses. Different vaccine subtypes have their unique advantages and disadvantages, discussed further in the next section.
Recombinant vaccines are usually composed of proteins that are not strong immunoactivators. Therefore, they require adjuvants to stimulate the innate immune system. This leads to the humoral response and proper inoculation. They are not needed for live-attenuated viruses. Different constituents can enhance and target different facets of the immune response. It is important to focus on the adjuvants in each vaccine trial and evaluate their role in eliciting a lasting humoral and cell-mediated response .
You May Like: What Ointment Is Good For Genital Herpes